Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model.
Autors de IIS La Fe
Autors aliens a IIS La Fe
- Algás R
- Sánchez M
Grups d'Investigació
Abstract
Cancer vaccines have always been a subject of gene therapy research. One of the most successful approaches has been working with genetically modified tumor cells. In this study, we describe our approach to achieving an immune response against a murine melanoma model, employing B16 tumor cells expressing GM-CSF and B7.2. Wild B16 cells were injected in C57BL6 mice to cause the tumor. Irradiated B16 cells transfected with GM-CSF, B7.2, or both, were processed as a preventive and therapeutic vaccination. Tumor volumes were measured and survival curves were obtained. Blood samples were taken from mice, and IgGs of each treatment group were also measured. The regulatory T cells (Treg) of selected groups were quantified using counts of images taken by confocal microscopy.
Dades de la publicació
- ISSN/ISSNe:
- 2072-6651, 2072-6651
- Tipus:
- Article
- Pàgines:
- 1058-1081
- PubMed:
- 23202306
- Factor d'Impacte:
- 0,731 SCImago ℠
- Quartil:
- Q2 SCImago ℠
Toxins MDPI AG
Cites Rebudes en Web of Science: 6
Documents
- No hi ha documents
Filiacions
Projectes associats
ESTUDIO DE FASE III, ALEATORIZADO, A DOBLE CIEGO, CONTROLADO CON PLACEBO SOBRE TERAPIA ADYUVANTE CON VEMURAFENIB (RO5185426) EN PACIENTES CON MELANOMA CUTÁNEO CON MUTACIÓN DE BRAF RESECADO QUIRÚRGICAMENTE CON ALTO RIESGO DE RECIDIVA.
Investigador Principal: ROBERTO PEDRO DÍAZ BEVERIDGE
GO27826 . 2013
ESTUDIO DE FASE III, ALEATORIZADO, ABIERTO QUE COMPARA LA COMBINACIÓN DEL INHIBIDOR DE BRAF, (DABRAFENIB) Y EL INHIBIDOR DE MEK (TRAMETINIB), CON EL INHIBIDOR DE BRAF (VEMURAFENIB) EN PACIENTES CON MELANOMA CUTÁNEO NO RESECABLE (ESTADIO IIIC) O METASTÁSIC O (ESTADIO IV) CON LA MUTACIÓN BRAF V600E/K.
Investigador Principal: ROBERTO PEDRO DÍAZ BEVERIDGE
MEK116513
LATENT. ESTIMACIÓN DE LA PREVALENCIA DE TUBERCULOSIS LATENTE EN PACIENTES CON PSORIASIS EN PLACAS MODERADA A GRAVE.
Investigador Principal: CONRAD PUJOL MARCO
PFI-ETA-2010-04